Terapia trombolítica del infarto cerebral agudo. Primer año de experiencia en Panamá 2003-2004.

Victor C Urrutia, Aron Benzadón, Ana C Arango

Resumen


RESUMEN:

La enfermedad cerebrovascular es la tercera causa de muerte en Panamá. Se presentan las indicaciones, contraindicaciones y protocolo para el uso del activador del plasminógeno tisular recombinante (rt-PA) como tratamiento activo para el infarto cerebral. Se detallan los dos primeros pacientes tratados en Panamá con esta terapia.

 

SUMMARY: The cerebrovascular disease (CVD) is the third cause of death in Panama. We
present the indications, contraindications and the protocol for the use of the activator of the
recombinant tissue plasminogen activator, as an active treatment for the cerebral impact. We bring
the details of the first two patients treated in Panama with this therapy.

 

Palabras clave: Enfermedad cerebrovascular, isquemia cerebral, infarto cerebral, terapia


Texto completo:

[PDF]

Referencias


Departamento de Análisis de Situación y

Tendencias de Salud, Sección de Estadísticas.

MINSA.

Sacco RL, Benjamín EJ, Broderick JP, et al: Risk

Factors Panel-American Heart Association Prevention

Conference IV. Stroke. 1997; 28:1507-1517.

Broderick J, Brott T, Kothari R, et al: The Greater

Cincinnati/Northern Kentucky Stroke Study:

Preliminary first-ever and total incidence rates of

strokes among blacks. Stroke. 1998; 29:415-421.

Pasternak RC, Criqui MH, Benjamin EJ, Fowkes

FGR, Isselbacher EM, et al: Atherosclerotic

Vascular Disease Conference, Writing Group I:

Epidemiology. Circulation. 2004; 109:2605-2612.

Saposnik G, Del Brutto OH: Sociedad

Iberoamericana de Enfermedades

Cerebrovasculares. Stroke in South America. A

systematic review of incidente, prevalence, and

stroke subtypes. Stroke. 2003; 34:2103-2108.

Sacco RL, Boden-Albala B, Gan R, Chen X,

Kargman DE, et al: Stroke incidence among white,

black, and Hispanic residents of an urban community:

The Northern Manhattan Stroke Study. American

Journal of Epidemiology. 1998; 147(3):259-268.

The National Institute of Neurological Disorders and

Stroke r-tPA Stroke Study Group. Tissue plasminogen

activator for acute ischemic stroke. N Engl J

Med. 1995; 333:1581-7.

Hacke W, Brott T, Caplan LR, et al: Thrombolysis in

acute ischemic stroke: Controlled trials and clinical

experience. Neurology. 1999; 53(suppl):S3-S14.

Buchan AM, Barber PA, Newcommon N, Karbalai

HG, Demchuk AM, Hoyte KM, Klein GM, Feasby

TE: Effectiveness of t-PA in acute ischemic stroke,

Outcome relates to appropriateness. Neurology.

; 54:679-684.

Lopez-Yunez AM, Bruno A, Williams LS, Yilmaz E,

Zurrú C, Biller J: Protocol violations in communitybased

rt-PA stroke treatment are associated with

symptomatic intracerebral hemorrhage. Neurology.

; 32:12-16.

Adams HP, Adams RJ, Brott T, del Zoppo GJ,

Furlan A, et al: Guidelines for the early management

of patients with ischemic stroke, a scientific

statement from the stroke council of the American

Stroke Association. Stroke. 2003; 34:1056-1083.

Albers GW, Bates VE, Clark WM, et al: Intravenous

tissue-type plasminogen activator for the

treatment of acute stroke: The Standard Treatment

with Activase to Reverse Stroke (STARS) study.

JAMA. 2000; 283:1145-1150.

Katzman IL, Furlan AJ, Lloyd Le, Frank JI, Harper

DL, et al: Use of tissue-type plasminogen activator

for acute ischemic stroke, the Cleveland area

experience. JAMA. 2000; 283:1151-58.

Joint Commission on Accreditation of Healthcare

Organizations. Primary Stroke Center Certification.

Fagan S, Morgenstern L, Pettita A, Ward RE, Tilley

BC, et al: Cost-effectiveness of tissue plasminogen

activator for acute ischaemic stroke. Neurology.

; 50: 883–890

Sandercock P, Berge E, Dennis M, Forbes J, Hand

P, et al: Cost-effectiveness of thrombolysis with

recombinant tissue plasminogen activator for acute

ischemic stroke assessed by a model based on UK

NHS costs. Stroke. 2004; 35:1490-1498.

Jorgensen HS, Kammersgaard LP, Houth J,

Nakayama H, Raaschou HO, et al: Who benefits

from treatment and rehabilitation in a stroke unit? : A

community-based study. Stroke. 2000; 31:434-439.

Jørgensen HS, Kammersgaard LP, Nakayama H,

Raaschou HO,Larsen K, et al: Treatment and

Rehabilitation on a Stroke Unit Improves 5-Year

Survival: A Community-Based Study. Stroke.1999;

: 930 - 933.

Evans A, Harraf F, Donaldson N, Kalra L: Randomized

controlled study of stroke unit care versus

stroke team care in different stroke subtypes.

Stroke. 2002; 33:449-455.

Lewandowski CA, Frankel M, Tomsick TA,

Broderick J, Frey J, the EMS Bridging Trial Investigators:

Combined intravenous and intra-arterial rt-

PA versus intra-arterial therapy of acute ischemic

stroke. Stroke; 30:2598-2605.

Ernst R, Pancioli A, Tomsick T, Kissela B, Woo D,

et al: Combined intravenous and intra-arterial

recombinant tissue plasminogen activator in acute

ischemic stroke. Stroke. 2000; 31:2552-2557.

Shaltoni HM, Noser EA, Hall CE, Ireland JK,

Wojner AW, et al: How safe is intra-arterial thrombolysis

following full-dose (0.9mg/kg) intravenous

TPA? Abstract presentado en el 29th International

Stroke Conference, 2004. San Diego, California.

EEUU.


Enlaces refback

  • No hay ningún enlace refback.


Académia Panameña de Medicina y Cirugía. Derechos reservados 2013. Un servicio de Infomedic International S,A.